{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"19.8","value":"7.7"},{"groupId":"OG001","lowerLimit":"3.3","upperLimit":"11.4","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"To assess progression-free survial (PFS) in patients receiving Pembrolizumab after radiation therapy for MPM.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patient with lung intact to receive hemithoracic radiation therapy for definitive intent","id":"OG000","title":"Cohort 1"},{"description":"Patients with lung intact to receive non-hemithoracic radiation therapy(palliative radiation therapy)","id":"OG001","title":"Cohort 2"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Every 6 weeks (42 +/- 7 days) until to 48 weeks, then every 12 weeks (+/- 7 days) to 5 years","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}